Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477529 · ClinicalTrials.gov registry record · Phase 1
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT00477529 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 102 participants.
The verdict
NCT00477529, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
Interventions
- DRUG ABI-008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2007-04-01 |
| Est. Completion | 2011-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477529
The ClinicalTrials.gov registry entry for NCT00477529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-008 is the first listed.
NCT00477529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477529 about?
NCT00477529 is a clinical study titled "ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer". To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
What is the current status of trial NCT00477529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2007-04-01. Estimated completion is 2011-06-02.
What interventions are being tested in trial NCT00477529?
The interventions under investigation include: ABI-008 (DRUG).
Who is sponsoring clinical trial NCT00477529?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.